Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research and pharmaceuticals: EU ‘pharming’ solutions to major diseases

22.07.2004


A team of European researchers plans to perfect techniques for producing antibodies and vaccines, obtained from plants, to prevent and treat major human diseases, such as AIDS, rabies and TB. The idea is to use genetically modified (GM) crops eventually to produce plant-based pharmaceuticals. Pharma-Planta is a consortium of eleven European countries and South Africa which, thanks to €12 million in EU funding, plans to produce vaccines and other treatments for major diseases, such as HIV/AIDS, rabies and tuberculosis. The project, led by the Fraunhofer Institute for molecular biology and ecology in Aachen (Germany), with scientific co-ordination by St George’s Hospital Medical School in London (UK), hopes to start clinical trials by the end of the funding period in 2009.

“The development of new drugs derived from plants, made possible thanks to recent advances in plant genetics, can benefit from cross-disciplinary collaboration at European level” commented Research Commissioner Philippe Busquin about this EU project. “The consortium of 39 research teams from across Europe and South Africa will combine expertise across disciplines, such as immunology and plant sciences, to offer real promise in this complex high-technology area.”

“Pharming”



Plant-based pharmaceutical production, or ‘pharming’, offers several advantages over traditional approaches. The current methods used to generate these types of treatments involve culturing cells or microorganisms, such as bacteria which are labour intensive, expensive and often only produce relatively small amounts of pharmaceuticals. But plants are inexpensive to grow and if “engineered” to contain a gene for a pharmaceutical product, they could produce large quantities of drugs or vaccines at low cost.

First concrete applications

The first product that might come out of the EU integrated project, possibly grown in maize, is likely to be an antibody that neutralises the AIDS virus. This could be incorporated for example, in a simple-to-apply microbicidal cream and used for blocking HIV transmission. Next would probably be a monoclonal antibody against rabies – still a major killer in the developing world and responsible for up to 70,000 deaths a year – which could be used after contracting the virus.

Checks and balances

The production of pharmaceuticals in GM plants would be subject to control by multiple regulatory agencies, including those governing the use of genetically modified organisms and those governing the production of drugs. Part of Pharma-Planta’s remit will also be to identify secure methods and places for production.

Although the consortium has yet to decide which plants to use, likely candidates include maize, tobacco and tomatoes. Plants possessing the desired proteins for producing so-called ‘immunotherapeutic bio-molecules’ – which can be found in high enough quantities in the seeds and harvested easily – will be given preference.

Fabio Fabbi | European Union
Further information:
http://www.europa.eu.int
http://www.pharma-planta.org

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>